Spero Therapeutics Q3 net loss narrows to $7.4M; GSK plans FDA filing for tebipenem HBr in Q4 2025

Spero Therapeutics, Inc.

2025-Q3 EPS reported -$0.41 vs consensus -$0.26 ▼ miss (-60.8%)

Net loss of $7.4M ($0.13 EPS) vs $17.1M ($0.32 EPS) in Q3 2024; revenue $5.4M, down from $13.5M.
Cash and equivalents $48.6M as of Sep 30, 2025; company expects funding into 2028.
Phase 3 PIVOT-PO trial of tebipenem HBr met primary endpoint; GSK to submit NDA to FDA in Q4 2025 with decision expected 2H 2026.
SPR720 program for NTM pulmonary disease discontinued in Q3 2025 after Phase 2a/1 data review.
R&D expenses fell to $8.6M from $26.9M due to lower PIVOT-PO and SPR720 costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.